Dr. Ralph Snyderman Receives 2007 Leadership in Personalized Medicine Award
News Nov 30, 2007
Ralph Snyderman, M.D., Chancellor Emeritus at Duke University and Founder and Chairman of Proventys, Inc., receives the 2007 Leadership in Personalized Medicine Award from the Personalized Medicine Coalition (PMC) for his efforts in advancing predictive and targeted therapies on a national scale.
The annual PMC award recognizes the contributions of a visionary individual whose actions in science, business, or policy have advanced the frontier of personalized medicine.
Dr. Snyderman accepted the award at the Harvard Medical School – Partners HealthCare Center for Genetics and Genomics (HPCGG) and Harvard Business School conference, Personalized Medicine: A Call for Action, in Boston, MA. (http://www.hpcgg.org/PM/2007/index.jsp)
“The PMC Leadership in Personalized Medicine Award publicly recognizes those individuals who support and contribute to the innovative and deeply collaborative nature of personalized medicine,” said Mara G. Aspinall, President of Genzyme Genetics, Vice Chair of the PMC, and Chair of the committee that selected Dr. Snyderman.
“Dr. Snyderman has helped advance the frontier of personalized medicine across a broad front, including clinical care, business, and as an outspoken supporter of the new paradigm.”
Personalized medicine is the use of molecular analysis to better manage a patient's disease or predisposition to disease in order to achieve optimal clinical outcomes by helping physicians and patients choose the approaches best suited to the patient's genetic and environmental profile.
Dr. Snyderman was appointed as a Howard Hughes Medical Investigator, assistant professor of medicine and immunology, and Chief of Rheumatology at the Durham Veteran's Administration at Duke University Medical Center in 1972.
Dr. Snyderman left Duke in 1987 to join Genentech, Inc., as Vice President, later becoming Senior Vice President. While at Genentech, he led the development and licensing of several novel therapeutics and supervised 300 staff members working in pharmacology, clinical research, and regulatory affairs.
As the Chancellor of Health Affairs at Duke from 1989 to 2004, Dr. Snyderman drew on his experience in biotechnology and healthcare delivery to conceive, pioneer, and implement a comprehensive healthcare approach based on the concept of “Prospective Health Care.”
Today, Dr. Snyderman continues to develop and advance his concept of prospective healthcare. After stepping down as Chancellor for Health Affairs at Duke, he founded the Center for Research on Prospective Health Care (CRPHC).
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.